Nicorandil PCD Pharma Franchise Company
Cafoli Lifecare is a trusted Nicorandil PCD pharma franchise company in India, offering a focused cardiac portfolio of 3 Nicorandil formulations in tablet form. Every batch is manufactured at WHO-GMP certified, DCGI-approved facilities and supplied to franchise partners with full monopoly rights, so distributors can build a stable anti-anginal business in their allotted territory.
What is Nicorandil?
Nicorandil is an anti-anginal agent with a dual mechanism of action: it opens ATP-sensitive potassium channels, causing arterial vasodilation and reducing cardiac afterload, and it also acts as a nitric oxide donor, dilating the veins and coronary arteries and reducing preload. It is used for the prophylaxis and long-term treatment of chronic stable angina pectoris, either alone or alongside beta-blockers and calcium channel blockers. Further pharmacological detail is available on PubChem.
Available Nicorandil Formulations
The Cafoli Lifecare Nicorandil range currently comprises 3 formulations, available in the following dosage form:
Product-wise brand names, compositions, pack sizes and net rates are shared with registered franchise enquiries. Contact our team for the current Nicorandil price list.
Therapeutic Applications of Nicorandil
Nicorandil is prescribed under medical supervision for:
- Prophylaxis and long-term treatment of chronic stable angina pectoris
- Add-on therapy where angina remains inadequately controlled on beta-blockers or calcium channel blockers
- Patients who are intolerant of, or have contraindications to, first-line anti-anginal agents
Prescriber specialties: cardiologists, consulting physicians and internal medicine specialists. Nicorandil is a prescription-only medicine and must be dispensed against a valid prescription.
Why Nicorandil is a High-Potential Molecule for Distributors
India carries one of the world's highest burdens of ischaemic heart disease, and angina management is overwhelmingly a chronic, repeat-prescription business — the same patient returns month after month, which gives Nicorandil unusually predictable secondary sales. Because Nicorandil is a second-line or add-on anti-anginal rather than a crowded first-line commodity like atenolol or amlodipine, the molecule sits in a less price-eroded segment with healthier margins. It is also strongly cardiologist-driven, so a distributor who builds relationships with a handful of cardiology clinics and cardiac care centres in a district can generate steady, defensible volumes without mass-market field expenditure.
Why Choose Cafoli Lifecare
- Monopoly rights — exclusive district-wise marketing rights for the Nicorandil range
- WHO-GMP certified manufacturing and DCGI-approved products
- Promotional inputs — visual aids, MR bags, prescription pads, samples and reminder cards
- 1000+ franchise partners across India and an on-time dispatch record
- Transparent net rates and dedicated franchise support
References
- PubChem — Nicorandil compound record
- PubMed — Nicorandil in stable angina (clinical literature)
- WHO Model List of Essential Medicines
Our formulations of Nicorandil find application in many critical therapeutic areas. Its therapeutic spectrum includes, but is not limited to: